Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — drug options
Prefer to look first? Browse the live map without signing up.
21 open options
- TRIALPHASE1RECRUITING
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
BnH-015B 5 mg · BnH-015B 10 mg · BnH-015B 20 mg — 1 site
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALPHASE2RECRUITING
Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
THC-free CBD Oil · Placebo — 1 site
- TRIALPHASE2RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Donanemab · Placebo — 72 sites
- TRIALNARECRUITING
EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment
Atrial fibrillation ablation + antiarrhythmic drugs · Antiarrhythmic drug — 8 sites
- TRIALPHASE3NOT_YET_RECRUITING
Alzheimer's Disease THErapy With NEuroaid II
MLC 901 · Placebo — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Psilocybin · Cognitive Training — 1 site
- TRIALPHASE2RECRUITING
Open-label Extension Study in Participants With Early Alzheimer's Disease
GSK4527226 — 33 sites
- TRIALPHASE1NOT_YET_RECRUITING
Escalating Doses of Memantine in Down Syndrome (MEDS-123)
Memantine — 1 site
- TRIALPHASE2RECRUITING
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Foralumab TZLS-401 50 µg · Foralumab TZLS-401 100 µg — 1 site
- TRIALPHASE2RECRUITING
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Placebo · Varenicline — 1 site
- TRIALPHASE2RECRUITING
Repurposing Siponimod for Alzheimer's Disease
Siponimod · Placebo — 1 site
- TRIALPHASE2ENROLLING_BY_INVITATION
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NSC001 · Placebo — 10 sites
- TRIALEARLY_PHASE1RECRUITING
Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease
Galcanezumab — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment
Metfomin — 1 site
- TRIALNARECRUITING
Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers
Acupuncture · Sham Acupuncture · Donepezil — 1 site
- TRIALPHASE4RECRUITING
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
Recombinant zoster vaccine · Placebo — 8 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA · Placebo — 55 sites
- TRIALPHASE2RECRUITING
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
[18F]-FEOBV Radiotracer — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.